Anzeige
Erschienen in:
01.10.2015 | Original Scientific Report
Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
Erschienen in: World Journal of Surgery | Ausgabe 10/2015
Einloggen, um Zugang zu erhaltenAbstract
Introduction
Breast cancer can be divided into four subtypes based on the expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor-2 (HER2). Each subtype has different clinicopathological features and outcomes.
Objective
To compare the clinicopathological features and survival of ER and/or PR positive HER2 negative (ER+PR+HER2−, ER+PR−HER2− or ER−PR+HER2−), ER and/or PR positive HER2 positive (ER+PR+HER2+, ER+PR−HER2+ or ER−PR+HER2+), ER negative PR negative HER2 positive (ER−PR−HER2+), and ER negative PR negative HER2 negative (ER−PR−HER2−) subtypes.
Methods
1957 patients with Stage 1–3 breast carcinoma diagnosed between Jan 2005 and Dec 2011 were categorized into the four subtypes. The clinicopathological features between the subtypes were compared using χ
2 test. Kaplan–Meier analysis was performed to estimate 5-year overall survival. Multivariate Cox regression was used to determine the association between subtypes and mortality adjusted for age, ethnicity, stage, pathological features, and treatment.
Results
ER−PR−HER2+ and ER−PR−HER2− subtypes were associated with younger age, larger tumors, and higher grade. There was no difference in the 5-year survival of the ER−PR−HER2+ and ER−PR−HER2− subtypes (75.1 and 74.4 %, respectively) and survival was poorer than in the ER and/or PR positive HER2 negative and ER and/or PR positive HER2 positive subtypes (87.1 and 83.1 %, respectively). Only 9.5 % of women with HER2 positive breast cancer had access to trastuzumab.
Conclusion
In a low resource setting with limited access to trastuzumab, there is no difference in survival between the ER−PR−HER2+ and ER−PR−HER2− subtypes of breast cancer.